Cue Biopharma Inc Ordinary Shares CUE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $29.46
- Day Range
- $27.53–32.60
- 52-Week Range
- $4.97–41.42
- Bid/Ask
- $29.50 / $30.72
- Shares Outstanding
- 4.20M
- Market Cap
- $126.01M
- Volume/Avg
- 38,107 / 732,371
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.37
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 29
- Website
- https://www.cuebiopharma.com
Valuation
|
Metric
|
CUE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.44 |
Price/Sales | 3.37 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CUE
|
|---|---|
Quick Ratio | 3.20 |
Current Ratio | 3.57 |
Interest Coverage | −112.03 |
Quick Ratio
CUE
Profitability
|
Metric
|
CUE
|
|---|---|
Return on Assets (Normalized) | −47.85% |
Return on Equity (Normalized) | −93.28% |
Return on Invested Capital (Normalized) | −72.56% |
Return on Assets
CUE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Wgnxpsvh | Nysqqws | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lnznngc | Zvcwhr | $67B | |||
| argenx SE ADR
ARGX
| Qvdjxksh | Mpx | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hlfhyqkf | Ckjsqn | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Ryxbpxskv | Zzpxdd | $25B | |||
| BioNTech SE ADR
BNTX
| Gvwszkc | Vtpc | $22B | |||
| Incyte Corp
INCY
| Dhctycb | Dysk | $20B | |||
| Moderna Inc
MRNA
| Glhcpstkm | Wry | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Dcxkcyz | Xcy | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Zznzftk | Fxss | $13B |
United States